ROBERTS EIRY 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 12, 2025
Insider Transaction Report
Form 4
ROBERTS EIRY
Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2025-02-08−1,860→ 0 total→ Common Stock (1,860 underlying) - Exercise/Conversion
Common Stock
2025-02-08+1,860→ 34,233 total - Sale
Common Stock
2025-02-10$118.22/sh−980$115,853→ 33,253 total
Footnotes (5)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]32,068 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
- [F4]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F5]This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award.